BACKGROUND: Pruritus can be a distressing and even debilitating symptom for patients with cutaneous T-cell lymphoma (CTCL). To date, few studies have evaluated the pathophysiology of this symptom. Because of this, therapy for pruritus in CTCL has mainly relied on those therapies that target and treat the lymphoma. For patients living with CTCL that relapses or becomes refractory to treatment, and who continue to experience severe itch, this lymphoma-targeted treatment may not be enough to combat their pruritus. Therefore, other itch-targeted therapies are needed for use in this disease. OBJECTIVE: We sought to evaluate the current evidence regarding the mechanism of action and treatments for pruritus associated with CTCL. METHODS: An explicit and thorough search was restricted to all peer-reviewed literature available through MEDLINE (1950 to September 2011) and PubMed. Search terms used were "pruritus," "cutaneous T-cell lymphoma," "CTCL," "mycosis fungoides," "MF," and "Sézary syndrome." All studies that involved pruritus in CTCL, mycosis fungoides, or Sézary syndrome were evaluated by all 3 authors. RESULTS: The current literature helps to identify therapies and possible mechanisms for treating patients with CTCL-associated pruritus. LIMITATION: Most studies were preclinical. Only studies involving mechanisms of action or treatment were included. CONCLUSION: A guideline is necessary to assist in the treatment of pruritus in CTCL and additional studies are necessary to uncover the exact mechanism or mechanisms of action.
BACKGROUND:Pruritus can be a distressing and even debilitating symptom for patients with cutaneous T-cell lymphoma (CTCL). To date, few studies have evaluated the pathophysiology of this symptom. Because of this, therapy for pruritus in CTCL has mainly relied on those therapies that target and treat the lymphoma. For patients living with CTCL that relapses or becomes refractory to treatment, and who continue to experience severe itch, this lymphoma-targeted treatment may not be enough to combat their pruritus. Therefore, other itch-targeted therapies are needed for use in this disease. OBJECTIVE: We sought to evaluate the current evidence regarding the mechanism of action and treatments for pruritus associated with CTCL. METHODS: An explicit and thorough search was restricted to all peer-reviewed literature available through MEDLINE (1950 to September 2011) and PubMed. Search terms used were "pruritus," "cutaneous T-cell lymphoma," "CTCL," "mycosis fungoides," "MF," and "Sézary syndrome." All studies that involved pruritus in CTCL, mycosis fungoides, or Sézary syndrome were evaluated by all 3 authors. RESULTS: The current literature helps to identify therapies and possible mechanisms for treating patients with CTCL-associated pruritus. LIMITATION: Most studies were preclinical. Only studies involving mechanisms of action or treatment were included. CONCLUSION: A guideline is necessary to assist in the treatment of pruritus in CTCL and additional studies are necessary to uncover the exact mechanism or mechanisms of action.
Authors: Jeanette Lundin; Hans Hagberg; Roland Repp; Eva Cavallin-Ståhl; Susanne Fredén; Gunnar Juliusson; Eija Rosenblad; Geir Tjønnfjord; Tom Wiklund; Anders Osterborg Journal: Blood Date: 2003-01-23 Impact factor: 22.113
Authors: Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross Journal: Nat Immunol Date: 2004-06-06 Impact factor: 25.606
Authors: E A Sausville; J L Eddy; R W Makuch; A B Fischmann; G P Schechter; M Matthews; E Glatstein; D C Ihde; F Kaye; S R Veach Journal: Ann Intern Med Date: 1988-09-01 Impact factor: 25.391
Authors: J Krutmann; A Köck; E Schauer; F Parlow; A Möller; A Kapp; E Förster; E Schöpf; T A Luger Journal: J Invest Dermatol Date: 1990-08 Impact factor: 8.551
Authors: Melania H Fanok; Amy Sun; Laura K Fogli; Vijay Narendran; Miriam Eckstein; Kasthuri Kannan; Igor Dolgalev; Charalampos Lazaris; Adriana Heguy; Mary E Laird; Mark S Sundrud; Cynthia Liu; Jeff Kutok; Rodrigo S Lacruz; Jo-Ann Latkowski; Iannis Aifantis; Niels Ødum; Kenneth B Hymes; Swati Goel; Sergei B Koralov Journal: J Invest Dermatol Date: 2017-11-08 Impact factor: 8.551
Authors: Filiberto Cedeno-Laurent; Elisha M Singer; Maria Wysocka; Bernice M Benoit; Carmela C Vittorio; Ellen J Kim; Gil Yosipovitch; Alain H Rook Journal: Clin Immunol Date: 2015-03-08 Impact factor: 3.969
Authors: Ellen J Kim; Youn H Kim; Alain H Rook; Adam Lerner; Madeleine Duvic; Sunil Reddy; Tadeusz Robak; Jürgen C Becker; Alexey Samtsov; William McCulloch; Joel Waksman; Sean Whittaker Journal: Leuk Lymphoma Date: 2015-05-20